XENON PHARMACEUTICALS INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
XENON PHARMACEUTICALS INC. (XENE) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $16.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $16.73M, a 22.02% increase year-over-year.
- XENON PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $16.89M, a 38.77% increase year-over-year.
- XENON PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $13.71M, a 5.41% increase year-over-year.
- XENON PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $13.71M, a 6.82% decline year-over-year.
- XENON PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $53.71M, a 5.90% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $50.72M, a 56.67% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $32.37M, a 58.87% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $20.38M, a 103.41% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $16.73M 10-Q · filed 2026-08-06 | $33.63M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $16.89M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $53.71M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $13.71M 10-Q · filed 2025-11-03 | $27.42M derived: sum of 2 quarters · filed 2026-08-06 | $39.59M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $13.71M 10-Q · filed 2026-08-06 | $25.89M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $12.17M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $50.72M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $13.00M 10-Q · filed 2025-11-03 | $27.72M derived: sum of 2 quarters · filed 2025-11-03 | $37.12M derived: sum of 3 quarters · filed 2025-11-03 | ||
| 2024-06-30 | $14.72M 10-Q · filed 2025-11-03 | $24.12M derived: sum of 2 quarters · filed 2025-11-03 | |||
| 2024-03-31 | $9.40M 10-Q · filed 2025-11-03 | ||||
| 2023-12-31 | $32.37M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $8.74M 10-Q · filed 2024-11-12 | $17.20M derived: sum of 2 quarters · filed 2024-11-12 | $23.19M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $8.45M 10-Q · filed 2024-11-12 | $14.45M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $5.99M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $20.38M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $5.74M 10-Q · filed 2023-11-08 | $10.95M derived: sum of 2 quarters · filed 2023-11-08 | $14.56M derived: sum of 3 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $5.21M 10-Q · filed 2023-11-08 | $8.82M derived: sum of 2 quarters · filed 2023-11-08 | |||
| 2022-03-31 | $3.61M 10-Q · filed 2023-11-08 | ||||
| 2021-12-31 | $10.02M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | $2.64M 10-Q · filed 2022-11-08 | $5.35M derived: sum of 2 quarters · filed 2022-11-08 | $7.31M derived: sum of 3 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $2.70M 10-Q · filed 2022-11-08 | $4.67M derived: sum of 2 quarters · filed 2022-11-08 | |||
| 2021-03-31 | $1.97M 10-Q · filed 2022-11-08 | ||||
| 2020-12-31 | $5.68M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | $1.58M 10-Q · filed 2021-11-10 | $3.05M derived: sum of 2 quarters · filed 2021-11-10 | $4.07M derived: sum of 3 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $1.47M 10-Q · filed 2021-11-10 | $2.49M derived: sum of 2 quarters · filed 2021-11-10 | |||
| 2020-03-31 | $1.01M 10-Q · filed 2021-11-10 | ||||
| 2019-12-31 | $2.93M 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | $630.00K 10-Q · filed 2020-11-05 | $1.10M derived: sum of 2 quarters · filed 2020-11-05 | $1.58M derived: sum of 3 quarters · filed 2020-11-05 | $2.24M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2019-06-30 | $470.00K 10-Q · filed 2020-11-05 | $946.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.61M derived: sum of 3 quarters · filed 2020-11-05 | $2.27M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2019-03-31 | $476.00K 10-Q · filed 2020-11-05 | $1.14M derived: sum of 2 quarters · filed 2020-11-05 | $1.80M derived: sum of 3 quarters · filed 2020-11-05 | $2.46M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2018-12-31 | $663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $1.32M derived: sum of 2 quarters · filed 2020-03-09 | $1.98M derived: sum of 3 quarters · filed 2020-03-09 | $2.65M 10-K · filed 2020-03-09 | |
| 2018-09-30 | $662.00K 10-Q · filed 2019-11-05 | $1.32M derived: sum of 2 quarters · filed 2019-11-05 | $1.99M 10-Q · filed 2018-11-06 | $2.59M derived: sum of 4 quarters · filed 2019-11-05 | |
| 2018-06-30 | $657.00K 10-Q · filed 2019-11-05 | $1.33M 10-Q · filed 2018-08-07 | $1.93M derived: sum of 3 quarters · filed 2019-11-05 | $2.52M derived: sum of 4 quarters · filed 2019-11-05 | |
| 2018-03-31 | $670.00K 10-Q · filed 2019-11-05 | $1.27M derived: sum of 2 quarters · filed 2019-11-05 | $1.86M derived: sum of 3 quarters · filed 2019-11-05 | $2.49M derived: sum of 4 quarters · filed 2019-11-05 | |
| 2017-12-31 | $598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $1.19M derived: sum of 2 quarters · filed 2019-03-06 | $1.82M derived: sum of 3 quarters · filed 2019-03-06 | $2.46M 10-K · filed 2019-03-06 | |
| 2017-09-30 | $591.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.23M derived: sum of 2 quarters · filed 2017-11-07 | $1.86M 10-Q · filed 2017-11-07 | $2.41M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2017-06-30 | $634.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $1.27M 10-Q · filed 2017-08-03 | $1.82M derived: sum of 3 quarters · filed 2018-03-07 | $2.35M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2017-03-31 | $637.00K 10-Q · filed 2017-05-09 | $1.19M derived: sum of 2 quarters · filed 2018-03-07 | $1.72M derived: sum of 3 quarters · filed 2018-03-07 | $2.19M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-12-31 | $548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $1.08M derived: sum of 2 quarters · filed 2018-03-07 | $1.55M derived: sum of 3 quarters · filed 2018-03-07 | $2.19M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $532.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.00M derived: sum of 2 quarters · filed 2016-11-03 | $1.64M 10-Q · filed 2016-11-03 | $2.11M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-06-30 | $472.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $1.11M 10-Q · filed 2016-08-03 | $1.58M derived: sum of 3 quarters · filed 2018-03-07 | $2.52M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-03-31 | $634.00K 10-Q · filed 2016-05-10 | $1.11M derived: sum of 2 quarters · filed 2018-03-07 | $2.05M derived: sum of 3 quarters · filed 2018-03-07 | $2.47M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2015-12-31 | $474.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $1.42M derived: sum of 2 quarters · filed 2018-03-07 | $1.84M derived: sum of 3 quarters · filed 2018-03-07 | $2.08M 10-K · filed 2018-03-07 | |
| 2015-09-30 | $942.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $1.36M derived: sum of 2 quarters · filed 2015-11-10 | $1.60M 10-Q · filed 2015-11-10 | $1.80M derived: sum of 4 quarters · filed 2017-03-08 | |
| 2015-06-30 | $422.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2015-08-13 | $661.00K 10-Q · filed 2015-08-13 | $860.00K derived: sum of 3 quarters · filed 2017-03-08 | ||
| 2015-03-31 | $239.00K 10-Q/A · filed 2015-08-13 | $288.00K 10-Q · filed 2015-05-12 | $438.00K derived: sum of 2 quarters · filed 2017-03-08 | ||
| 2014-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $760.00K 10-K · filed 2017-03-08 | |||
| 2014-09-30 | $561.00K 10-Q · filed 2014-12-15 | ||||
| 2013-12-31 | $575.00K 10-K · filed 2016-03-08 | ||||
| 2012-12-31 | $406.00K 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |